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COST-EFFECTIVENESS OF CEFEPIME VERSUS
CEFOTAXIME WHEN ADDED TO
METRONIDAZOLE IN COMPLICATED
INTRAABDOMINAL INFECTIONS
Salas M1, Caro J1, Molinar F2
1Caro Research Institute, Concord, MA, USA; 2Intensive Care
Unit, Medical Center “La Raza”, Mexico City, Mexico
OBJECTIVES: Intraabdominal infections, with their high
morbidity and mortality, represent an immense treatment
challenge because multiple microorganisms are involved.
The addition of cefepime to metronidazole has been
shown to be effective but the cost of the drug is high.
Therefore, the objective of this study was to assess the
cost-effectiveness of this combination compared to cefo-
taxime-metronidazole from the perspective of the third-
party payer. METHODS: Data were obtained on the
resources consumed by 60 adults with intraabdominal
infection enrolled in a randomized trial carried out in the
Intensive Care Unit, Hospital of Specialties “La Raza”,
Mexico City comparing cefepime to cefotaxime, both in
addition to metronidazole. Clinical cure, improvement or
failure, was determined according to presence of symp-
toms while bacteriological cure depended on absence of
the initial microorganisms. For the economic study, data
on length of stay (LOS); use of special care units, labo-
ratory tests, radiology, nuclear medicine or other special
studies; number and type of surgeries as well as duration
of antimicrobial treatment were collected. Information
was extracted from patient charts and case report forms.
Unit costs were obtained from the hospital’s Finance
Department and are reported in 2001 US dollars (1 USD
= 10 MEX). RESULTS: There were no statistically sig-
niﬁcant differences between groups in age, gender,
number and type of diagnoses or severity of disease.
Staphylococcus aureus, Streptococcus spp, Escherichia
coli, Enterococcus spp and Pseudomona aeuruginosa
were most frequently isolated. There were no statisti-
cally signiﬁcant differences in the number and type of
tests. Clinical and bacteriologic efﬁcacy were similar 
between groups. However, patients receiving cefepime-
metronidazole had shorter LOS than patients receiving
cefotaxime-metronidazole (mean 21 days versus 27 days,
respectively) and thus lower total hospitalization costs
(mean $18,974 for cefepime-metronidazole vs. $20,092
for cefotaxime-metronidazole). Including the cost of the
drugs, the difference is reduced to $503 in favor of
cefepime-metronidazole. CONCLUSIONS: The combi-
nation of cefepime with metronidazole reduces average
total costs resulting in economic dominance over 
cefotaxime.
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ESTIMATED COST SAVINGS OF
DISCONTINUING SECONDARY PROPHYLAXIS
FOR OPPORTUNISTIC INFECTIONS AFTER
IMMUNOLOGICAL RECONSTITUTION 
WITH HAART
Becker RV, Gams E, Shakur IM
Ovation Research Group, Highland Park, IL, USA
OBJECTIVE: Three studies presented at the XIV Inter-
national AIDS conference in Barcelona, Spain give sup-
port to the discontinuation of secondary prophylaxis (SP)
of cryptocycoccal meningitis (CM), mycobacterium
avium (MAC), and disseminated histoplamosis (DH)
after immunological reconstitution with HAART. Our
objective was to estimate potential cost savings of with-
drawing secondary prophylaxis. METHODS: Three sep-
arate analyses were performed, one for each opportunistic
infection (OI) analyzed and were each comprised of 100
HIV-infected patients who were assumed to be naïve for
antiretroviral therapy and previously diagnosed with one
of the given OI’s. As in the prophylaxis studies, we
assumed that all patients were receiving HAART and 
secondary prophylaxis for six months. Clinical outcomes
following six months were taken from the prophy-
laxis studies and previously published HAART studies.
HAART and SP drug costs (2002 U.S. AWP) from the
payer perspective were determined for the period follow-
ing 6 months of HAART treatment through the duration
of each given prophylaxis-study time frame (11 months
for CM, 12 months for MAC, and 16 months for DH).
The number of patients in the cohort who could poten-
tially discontinue SP was calculated as was their per-
patient costs. Similar estimations were made for patients
who could not discontinue (including HAART non-
responders). Discounting was not performed due to the
short analytical timeframe. RESULTS: In the CM cohort,
42 patients discontinued SP at a monthly cost of
$1052.31 per patient versus $1449.61 for the remaining
76 patients not discontinuing (27.4% savings per dis-
continuation). In the MAC cohort, 24 patients discontin-
ued SP at a cost of $1052.31 per patient versus $1463.57
for the remainder (28.1% savings), and $1052.31 per
patient in the DH cohort where all patients discontinued
(30.7% savings). CONCLUSION: Given that discontinue
secondary prophylaxis is considered safe after immuno-
logical reconstitution with HAART, the potential cost
savings can be substantial.
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PHARMACOECONOMIC EVALUATION OF
ANTIMICROBIAL AGENTS IN THE TREATMENT
OF SEXUALLY TRANSMITTED DISEASES IN
LAGOS UNIVERSITY TEACHING HOSPITAL
Suleiman IA,Tayo F
College of Medicine, University of Lagos, Lagos, Nigeria
Increasing awareness of the utmost need for the limited
resources to be used more efﬁciently has called for eco-
